Cigna Healthcare, the health benefits division of the Cigna Group, has released a set of digital tools aimed at improving the ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Cigna trades at $313 per share and has moved ... customers’ monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. Beginning in the second half of 2025, the program ...

Recognition Follows Claimable's Launch of GLP-1 Support, Helping Patients Navigate One of the Most Denied Treatments in the U ...

Cigna to offer $200 Wegovy, Zepbound weight-loss benefit Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an add-on to its ...

News outlets break down the health effects rubber bullets and tear gas have on people, and how the use of such methods could open up governments to civil liability claims. Other states making news: ...

Eli Lilly is claiming another victory in a head-to-head trial comparing its weight-loss drug Zepbound to its main rival Wegovy from Novo Nordisk. The full data from the 751-subject SURMOUNT-5 ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid ...

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Search for Symbols, analysts, keywords ...